{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:05:29Z","timestamp":1784559929815,"version":"3.55.0"},"reference-count":49,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy of secukinumab on axial and peripheral enthesitis in patients with ankylosing spondylitis (AS) using pooled data from randomized controlled phase III studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this posthoc analysis, data were pooled from patients originally randomized to secukinumab 150 mg, 300 mg, or placebo (PBO) from phase III MEASURE 1\u20134 studies (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01358175\">NCT01358175<\/jats:ext-link>,  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01649375\">NCT01649375<\/jats:ext-link>,  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02008916\">NCT02008916<\/jats:ext-link>, and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02159053\">NCT02159053<\/jats:ext-link>). Maastricht AS Enthesitis Score (MASES) was used for assessments of enthesitis through Week 52. Efficacy outcomes were mean change in MASES score and complete resolution (MASES = 0) of enthesitis in patients with baseline MASES &gt; 0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 693 (71.5%) patients had enthesitis at baseline in secukinumab 300 mg, 150 mg, and PBO groups (58 [76.3%], 355 [70.4%], and 280 [72%], respectively) out of 969 patients pooled in this analysis. At Week 16, mean changes from baseline for overall MASES and enthesitis at axial MASES sites, respectively, were as follows: \u20132.9 (<jats:italic>P<\/jats:italic> &lt; 0.01) and \u20132.9 (<jats:italic>P<\/jats:italic> &lt; 0.01) for secukinumab 300 mg; \u20132.4 (<jats:italic>P<\/jats:italic> &lt; 0.015) and \u20132.3 (<jats:italic>P<\/jats:italic> &lt; 0.05) for secukinumab 150 mg; and \u20131.9 and \u20131.8 for PBO, with improvements seen through Week 52. More than one-third of secukinumab-treated patients (300 mg: 36.2%; 150 mg: 40.8%) achieved complete resolution of enthesitis at Week 16.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Secukinumab improved enthesitis at overall MASES and axial sites in patients with AS.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.201111","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T12:20:29Z","timestamp":1615810829000},"page":"1251-1258","source":"Crossref","is-referenced-by-count":16,"title":["Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies"],"prefix":"10.3899","volume":"48","author":[{"given":"Georg","family":"Schett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayan Das","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shephard","family":"Mpofu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Winseck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Shete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"2022062114102972000_48.8.1251.1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/art.39458","article-title":"Review: enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment","volume":"68","author":"Kehl","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022062114102972000_48.8.1251.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2003.10.010"},{"key":"2022062114102972000_48.8.1251.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.188"},{"key":"2022062114102972000_48.8.1251.4","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/art.40150","article-title":"Brief report: group 3 innate lymphoid cells in human enthesis","volume":"69","author":"Cuthbert","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022062114102972000_48.8.1251.5","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2854"},{"key":"2022062114102972000_48.8.1251.6","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817"},{"key":"2022062114102972000_48.8.1251.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138701"},{"key":"2022062114102972000_48.8.1251.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.03.007"},{"key":"2022062114102972000_48.8.1251.9","first-page":"727","article-title":"A short-term follow-up of enthesitis and arthritis in the active phase of juvenile onset spondyloarthropathies","volume":"20","author":"Burgos-Vargas","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114102972000_48.8.1251.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"2022062114102972000_48.8.1251.11","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C"},{"key":"2022062114102972000_48.8.1251.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.127"},{"key":"2022062114102972000_48.8.1251.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"},{"key":"2022062114102972000_48.8.1251.14","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/acr.23534","article-title":"Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-based Corrona registry","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2022062114102972000_48.8.1251.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.38140"},{"key":"2022062114102972000_48.8.1251.16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2022062114102972000_48.8.1251.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064543"},{"key":"2022062114102972000_48.8.1251.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2022062114102972000_48.8.1251.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201370"},{"key":"2022062114102972000_48.8.1251.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201252"},{"key":"2022062114102972000_48.8.1251.21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022062114102972000_48.8.1251.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"2022062114102972000_48.8.1251.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"2022062114102972000_48.8.1251.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"2022062114102972000_48.8.1251.25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/OARRR.S116654","article-title":"Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy","volume":"10","author":"Marin","year":"2018","journal-title":"Open Access Rheumatol"},{"key":"2022062114102972000_48.8.1251.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087270"},{"key":"2022062114102972000_48.8.1251.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.23901"},{"key":"2022062114102972000_48.8.1251.28","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.993378"},{"key":"2022062114102972000_48.8.1251.29","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.899351"},{"key":"2022062114102972000_48.8.1251.30","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283524b82"},{"key":"2022062114102972000_48.8.1251.31","doi-asserted-by":"publisher","DOI":"10.1186\/ar1693"},{"key":"2022062114102972000_48.8.1251.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.11325"},{"key":"2022062114102972000_48.8.1251.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"2022062114102972000_48.8.1251.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"2022062114102972000_48.8.1251.35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","article-title":"Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study","volume":"58","author":"Braun","year":"2019","journal-title":"Rheumatology"},{"key":"2022062114102972000_48.8.1251.36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000592"},{"key":"2022062114102972000_48.8.1251.37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2022062114102972000_48.8.1251.38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2022062114102972000_48.8.1251.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.2560"},{"key":"2022062114102972000_48.8.1251.40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"2022062114102972000_48.8.1251.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"2022062114102972000_48.8.1251.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2022062114102972000_48.8.1251.43","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-18"},{"key":"2022062114102972000_48.8.1251.44","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2022062114102972000_48.8.1251.45","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2022062114102972000_48.8.1251.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2022062114102972000_48.8.1251.47","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-1027-5"},{"key":"2022062114102972000_48.8.1251.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.09.010"},{"key":"2022062114102972000_48.8.1251.49","doi-asserted-by":"crossref","unstructured":"Baraliakos X , Coates L , Gossec L , Jeka S , Mera A , Schulz B , Secukinumab improves axial manifestations in patients with psoriatic arthritis and inadequate response to NSAIDs: primary analysis of phase 3 trial [abstract]. Arthritis Rheumatol 2019; 71 Suppl 10.","DOI":"10.1136\/annrheumdis-2019-eular.2932"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.201111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:18:26Z","timestamp":1655846306000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.201111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,1]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.3899\/jrheum.201111"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.201111","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]}}}